399 related articles for article (PubMed ID: 24922010)
1. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.
Tsujino K; Hashimoto T; Shimada T; Yoden E; Fujii O; Ota Y; Satouchi M; Negoro S; Adachi S; Soejima T
J Thorac Oncol; 2014 Jul; 9(7):983-990. PubMed ID: 24922010
[TBL] [Abstract][Full Text] [Related]
2. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
[TBL] [Abstract][Full Text] [Related]
3. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
[TBL] [Abstract][Full Text] [Related]
4. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
[TBL] [Abstract][Full Text] [Related]
5. Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients.
Alharbi M; Janssen S; Golpon H; Bremer M; Henkenberens C
Radiat Oncol; 2017 Nov; 12(1):165. PubMed ID: 29096667
[TBL] [Abstract][Full Text] [Related]
6. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study.
Rancati T; Ceresoli GL; Gagliardi G; Schipani S; Cattaneo GM
Radiother Oncol; 2003 Jun; 67(3):275-83. PubMed ID: 12865175
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.
Boonyawan K; Gomez DR; Komaki R; Xu Y; Nantavithya C; Allen PK; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):919-926. PubMed ID: 29976504
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer.
Tsujino K; Hirota S; Endo M; Obayashi K; Kotani Y; Satouchi M; Kado T; Takada Y
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):110-5. PubMed ID: 12504042
[TBL] [Abstract][Full Text] [Related]
9. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.
Chen F; Niu J; Wang M; Zhu H; Guo Z
Radiat Oncol; 2024 May; 19(1):67. PubMed ID: 38816745
[TBL] [Abstract][Full Text] [Related]
10. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
[TBL] [Abstract][Full Text] [Related]
11. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
[TBL] [Abstract][Full Text] [Related]
12. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation.
Tsujino K; Hirota S; Kotani Y; Kado T; Yoden E; Fujii O; Soejima T; Adachi S; Takada Y
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1100-5. PubMed ID: 16373082
[TBL] [Abstract][Full Text] [Related]
13. Predicting radiation pneumonitis in locally advanced stage II-III non-small cell lung cancer using machine learning.
Luna JM; Chao HH; Diffenderfer ES; Valdes G; Chinniah C; Ma G; Cengel KA; Solberg TD; Berman AT; Simone CB
Radiother Oncol; 2019 Apr; 133():106-112. PubMed ID: 30935565
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.
Ueyama T; Arimura T; Takumi K; Nakamura F; Higashi R; Ito S; Fukukura Y; Umanodan T; Nakajo M; Koriyama C; Yoshiura T
Br J Radiol; 2018 Jun; 91(1086):20170453. PubMed ID: 29565649
[TBL] [Abstract][Full Text] [Related]
15. Ipsilateral lung dose as a correlative measure for radiation pneumonitis in patients treated with definitive concurrent radiochemotherapy.
Kirakli EK; Erdem S; Susam S; Erim E
J Cancer Res Ther; 2023; 19(5):1153-1159. PubMed ID: 37787278
[TBL] [Abstract][Full Text] [Related]
16. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
[TBL] [Abstract][Full Text] [Related]
17. Novel model integrating computed tomography-based image markers with genetic markers for discriminating radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer receiving radiotherapy: a retrospective multi-center radiogenomics study.
Li J; Li L; Tang S; Yu Q; Liu W; Liu N; Yang F; Zhang D; Yuan S
BMC Cancer; 2024 Jan; 24(1):78. PubMed ID: 38225543
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Which Dose-Function Metrics Are Most Critical for Functional-Guided Radiation Therapy.
Faught AM; Yamamoto T; Castillo R; Castillo E; Zhang J; Miften M; Vinogradskiy Y
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):202-209. PubMed ID: 28816147
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Lee YH; Choi HS; Jeong H; Kang KM; Song JH; Lee WS; Lee GW; Song HN; Kim HG; Kang MH; Rhee DY; Jeong BK
Clin Respir J; 2018 Mar; 12(3):1264-1273. PubMed ID: 28618180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
